P.A.W. Capital Partners’ Returns, AUM, and Holdings

The largest two positions P.A.W. Capital Partners held at the end of the third quarter were in Attunity Ltd (NASDAQ:ATTU) and Allot Ltd (NASDAQ:ALLT) occupying 4.81% and 4.59% of its 13F portfolio, respectively. The fund actually lowered its stake in software company Attunity Ltd (NASDAQ:ATTU) by 20% to 240,000 shares, which were valued at $4.53 million at the end of September. In Allot Ltd (NASDAQ:ALLT), the fund also reduced its stake, but by just 3% to 700,000 shares worth $4.33 million.

In the meantime, the biggest new additions to the fund’s portfolio were stakes in Pieris Pharmaceuticals Inc (NASDAQ:PIRS), in which the fund obtained 250,000 shares valued at $1.4 million, and The Rubicon Project Inc (NYSE:RUBI), 300,000 shares of which were bought by P.A.W. It’s been a completely story on the stock market in 2018 for Pieris Pharmaceuticals Inc (NASDAQ:PIRS), whose shares are down by 50%, and the Rubicon Project Inc (NYSE:RUBI), whose shares have jumped by 54.8%.

Among the companies, P.A.W. Capital Partners seemed to lose optimism for during Q3 were Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) and AT&T Inc. (NYSE:T), in which the fund lowered its stakes by 62% to 35,000 shares, and by 45% to 25,000 shares, respectively. It is interesting to see that the fund is reducing its stake in AT&T Inc. (NYSE:T), as the company was the 10^th most popular stock among the hedge funds tracked by Insider Monkey’s database at the end of the second quarter (see the list of the 25 most popular stocks among hedge funds). The biggest positions the fund decided to sell during the third quarter included Akebia Therapeutics Inc (NASDAQ:AKBA), in which it held 100,000 shares valued at $998,000 on March 31, and MacroGenics Inc (NASDAQ:MGNX), in which the fund had held a position valued at $516,000 that counted 25,000 shares.

Disclosure: None